Oxaprozin

• CAT Number: A001002
• CAS Number: 21256-18-8
• Molecular Formula: C18H15NO3
• Molecular Weight: 293.3
• Purity: ≥95%
• Synonyms: 21256-18-8; Daypro; Alvo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; Oxaprozine
• Target: NF-κB
• Storage: -20°C
• InChI: 1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
• InChIKey: OFPXSFXSNFPTHF-UHFFFAOYSA-N
• SMILES: C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3

Oxaprozin is a non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative.

Reference

1: Peesa JP, Atmakuri LR, Yalavarthi PR, Mandava Venkata BR, Rasheed A, Pachava
V. Oxaprozin prodrug as safer nonsteroidal anti-inflammatory drug: Synthesis and
pharmacological evaluation. Arch Pharm (Weinheim). 2017 Dec 28. doi:
10.1002/ardp.201700256. [Epub ahead of print] PubMed PMID: 29283449.

2: Maestrelli F, Mura P, Cirri M, Mennini N, Ghelardini C, Di Cesare Mannelli L.
Development and characterization of fast dissolving tablets of oxaprozin based on
hybrid systems of the drug with cyclodextrins and nanoclays. Int J Pharm. 2017
Oct 15;531(2):640-649. doi: 10.1016/j.ijpharm.2017.05.033. Epub 2017 May 15.
PubMed PMID: 28522425.

3: Mennini N, Cirri M, Maestrelli F, Mura P. Comparison of liposomal and NLC
(nanostructured lipid carrier) formulations for improving the transdermal
delivery of oxaprozin: Effect of cyclodextrin complexation. Int J Pharm. 2016 Dec
30;515(1-2):684-691. doi: 10.1016/j.ijpharm.2016.11.013. Epub 2016 Nov 5. PubMed
PMID: 27825863.

4: Mennini N, Maestrelli F, Cirri M, Mura P. Analysis of physicochemical
properties of ternary systems of oxaprozin with randomly
methylated-ß-cyclodextrin and l-arginine aimed to improve the drug solubility. J
Pharm Biomed Anal. 2016 Sep 10;129:350-358. doi: 10.1016/j.jpba.2016.07.024. Epub
2016 Jul 18. PubMed PMID: 27454086.

5: Mura P, Maestrelli F, Aguzzi C, Viseras C. Hybrid systems based on /drug – in
cyclodextrin – in nanoclays/ for improving oxaprozin dissolution properties. Int
J Pharm. 2016 Jul 25;509(1-2):8-15. doi: 10.1016/j.ijpharm.2016.05.028. Epub 2016
May 14. PubMed PMID: 27188644.

6: Lopes-de-Araújo J, Neves AR, Gouveia VM, Moura CC, Nunes C, Reis S.
Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects.
Pharm Res. 2016 Feb;33(2):301-14. doi: 10.1007/s11095-015-1788-x. Epub 2015 Sep
9. PubMed PMID: 26350105.

7: Mao M, Wang L, Jiang X, Yang L. [Determination of oxaprozin in human plasma
with high performance liquid chromatography (HPLC) and its application]. Sheng Wu
Yi Xue Gong Cheng Xue Za Zhi. 2013 Jun;30(3):646-50. Chinese. PubMed PMID:
23865335.

8: Božić BD, Rogan JR, Poleti DD, Trišović NP, Božić BD, Ušćumlić GS. Synthesis,
characterization and antiproliferative activity of transition metal complexes
with 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid (oxaprozin). Chem Pharm Bull
(Tokyo). 2012;60(7):865-9. PubMed PMID: 22790819.

9: Maestrelli F, Cirri M, Mennini N, Zerrouk N, Mura P. Improvement of oxaprozin
solubility and permeability by the combined use of cyclodextrin, chitosan, and
bile components. Eur J Pharm Biopharm. 2011 Aug;78(3):385-93. doi:
10.1016/j.ejpb.2011.03.012. Epub 2011 Mar 23. PubMed PMID: 21439375.

10: Kara IM, Polat S, Inci MF, Gümüş C. Analgesic and anti-inflammatory effects
of oxaprozin and naproxen sodium after removal of impacted lower third molars: a
randomized, double-blind, placebo-controlled crossover study. J Oral Maxillofac
Surg. 2010 May;68(5):1018-24. doi: 10.1016/j.joms.2009.09.094. Epub 2010 Mar 5.
Erratum in: J Oral Maxillofac Surg. 2010 Aug;68(8):2036. J Oral Maxillofac Surg.
2011 Dec;69(12):3051. Ince, Fatih [corrected to Inci, M Fatih]. PubMed PMID:
20206429.